Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05204927 is registered in ClinicalTrials.gov with Curium US LLC as lead sponsor.

NCT NCT05204927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05204927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T Versus Hormone Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Curium US LLC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 14, 2022
Completion date
February 28, 2029
Enrollment
439 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

metastasis from malignant tumor of prostate